Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.

@article{Marschner1991DoubleblindRT,
  title={Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.},
  author={Norbert Marschner and M. R. Adler and Gerd Arno Nagel and Daniel Christmann and E Fenzl and B N Upadhyaya},
  journal={European journal of cancer},
  year={1991},
  volume={27 9},
  pages={1137-40}
}
Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer. All patients were treated with epirubicin (greater than 50 mg/m2) and cyclophosphamide (greater than 500 mg/m2). 50 patients receiving ondansetron and 60 with metoclopramide were considered evaluable. Ondansetron was at least as effective as metoclopramide in the control of vomiting and nausea. The percentage of patients with complete plus major… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

5‐HT3 antiemetic therapy for patients with breast cancer

Breast Cancer Research and Treatment • 1999
View 2 Excerpts

Similar Papers

Loading similar papers…